Ureteral Stents Market By Product Type (Double J Stents, Single Pigtail Stents, Multi-Purpose Stents), By Material (Silicone Stents, Polyurethane Stents, Other Biocompatible Stents), By Application (Ureteral Obstruction, Stone Extraction, Urinary Tract Procedures), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Ureteral Stents Market was valued at USD 981.2 million in 2024-e and will surpass USD 1,926.2 million by 2030; growing at a CAGR of 11.9% during 2025 - 2030.

The global ureteral stents market is growing rapidly due to increasing incidences of urinary tract disorders, kidney stones, and ureteral obstructions that require effective management through stent placement. Ureteral stents are medical devices used to maintain the patency of the ureter, often during procedures for stone extraction or to treat obstructions in the urinary tract. The market is also driven by the rising prevalence of chronic conditions like kidney stones, urinary tract infections, and cancer-related obstructions. Stents serve a crucial role in ensuring the proper flow of urine from the kidneys to the bladder, helping to prevent kidney damage or other complications.

With advancements in materials and designs, ureteral stents are becoming more efficient and comfortable for patients. The adoption of biocompatible materials, such as silicone and polyurethane, has led to better patient outcomes with fewer complications such as infections or encrustation. Moreover, innovations in stent designs, such as the development of multi-purpose stents and the continuous improvement of deployment techniques, are further fueling market growth. As healthcare systems increasingly focus on minimally invasive procedures, the demand for ureteral stents is expected to continue rising.

Double J Stents Are Largest Owing to Widespread Use and Versatility

Double J stents hold the largest market share in the ureteral stents market due to their versatility and widespread use in various urological procedures. Double J stents are designed to help maintain the patency of the ureter by preventing obstruction and promoting the flow of urine, which is especially important in conditions such as ureteral obstructions, after kidney stone surgery, and during post-surgical recovery. These stents are named after their double "J" shape, which ensures that they securely anchor both in the kidney and the bladder, reducing the risk of dislodgement.

The popularity of Double J stents is driven by their high success rate, ease of use, and effectiveness in managing urinary tract issues. They are commonly used in hospitals for procedures involving kidney stones and other ureteral blockages. Their design allows for easy insertion and removal, and they are typically well tolerated by patients. With continuous advancements in materials that improve patient comfort and reduce complications, Double J stents remain the most commonly used ureteral stents, cementing their position as the largest product type in the market.

Silicone Stents Are Largest Material Type Owing to Biocompatibility and Safety

Silicone stents dominate the ureteral stents market in terms of material due to their high biocompatibility, safety, and lower risk of encrustation or infection compared to other materials. Silicone is a highly flexible and durable material that reduces the risk of irritation or damage to the ureter during prolonged use. This makes silicone stents particularly beneficial for patients who require long-term stenting, such as those with chronic ureteral obstructions or after major surgeries like stone extraction.

The excellent biocompatibility of silicone ensures that these stents can be safely used in the body for extended periods without causing adverse reactions. Silicone stents are also less likely to form deposits or become encrusted with minerals, which can often lead to complications with other materials. As a result, silicone stents are preferred by healthcare providers in a wide range of applications, from ureteral obstruction management to stone extraction, making them the most widely used material in the ureteral stent market.

Ureteral Obstruction Application Is Largest Owing to Prevalence of Obstructions

The ureteral obstruction application segment holds the largest market share, driven by the high prevalence of conditions that cause blockages in the ureter, such as kidney stones, tumors, and strictures. Ureteral obstructions can lead to serious complications, including kidney damage, urinary retention, and infection if not treated promptly. Stenting is one of the most common treatments used to alleviate these obstructions and ensure the continued flow of urine.

Stenting for ureteral obstructions is crucial for both short-term and long-term management, allowing for the drainage of urine from the kidneys to the bladder while treating the underlying condition. The widespread use of ureteral stents for obstruction-related conditions continues to grow as awareness of these disorders increases and as the demand for minimally invasive, effective treatments rises. The efficacy of stents in treating ureteral obstructions, combined with their ease of use, ensures their dominance in the market.

Hospitals End-User Segment Is Largest Owing to High Patient Volume and Specialized Care

The hospitals segment is the largest end-user category in the ureteral stents market due to the high volume of patients requiring treatment for conditions like kidney stones, ureteral obstructions, and other urinary tract disorders. Hospitals are typically equipped with the necessary infrastructure and medical expertise to perform stent insertions and removals in a safe and controlled environment. The use of ureteral stents in hospitals is critical for treating a wide range of acute and chronic conditions, particularly in emergency situations or for patients undergoing major surgeries.

Hospitals provide a broad spectrum of care for patients with urological issues, including diagnostic procedures, stent placements, and post-surgical care. The high patient turnover and the need for specialized care drive the continued demand for ureteral stents in these settings. Additionally, hospitals often have the resources and expertise to manage complications associated with stenting, ensuring the effective treatment of complex cases. As the healthcare sector continues to prioritize efficient, minimally invasive treatments, hospitals will remain the dominant end-user of ureteral stents.

North America Is the Largest Region Owing to Advanced Healthcare Systems and High Incidence of Urological Disorders

North America is the largest region in the ureteral stents market, owing to its advanced healthcare infrastructure, high incidence of urological disorders such as kidney stones, and extensive use of stent-based treatments in clinical practice. The U.S. in particular has a high prevalence of urological conditions, with kidney stones being one of the most common issues requiring stent placement. The region’s well-established healthcare systems and widespread access to advanced medical technologies support the strong demand for ureteral stents.

In addition to high treatment volumes, North America is a hub for research and development in the field of urology, which leads to innovations in stent materials, designs, and application techniques. The region also benefits from strong regulatory support and a favorable reimbursement landscape, further promoting the growth of the ureteral stents market. As a result, North America continues to be the largest and most influential market for ureteral stents.

Competitive Landscape: Key Players and Technological Advancements

The ureteral stents market is competitive, with key players such as Boston Scientific Corporation, Cook Medical, and Teleflex Incorporated leading the development and distribution of ureteral stents. These companies focus on enhancing the materials and designs of their stents to improve patient comfort, reduce complications, and optimize clinical outcomes. Innovations such as bioabsorbable stents, which eliminate the need for removal, and stents with improved anti-infection properties, are contributing to the evolution of the market.

As healthcare providers seek more effective and minimally invasive solutions for treating ureteral conditions, companies are continuously investing in research and development to offer new and improved stent technologies. Additionally, strategic partnerships and acquisitions are common as players seek to expand their portfolios and strengthen their positions in the market. With increasing competition and technological advancements, the ureteral stents market is poised for continued growth, offering new opportunities for patients and healthcare providers alike.

Recent Developments:

• In December 2024, Boston Scientific Corporation launched a new polyurethane-based ureteral stent with improved patient comfort.
• In November 2024, Teleflex Incorporated announced a collaboration with a leading hospital group to provide advanced ureteral stent solutions.
• In October 2024, Cook Medical received regulatory approval for its next-generation stent with enhanced durability for long-term use.
• In September 2024, Medtronic introduced a silicone-coated ureteral stent designed to reduce friction and ease insertion.
• In August 2024, Coloplast A/S unveiled its new range of biodegradable ureteral stents aimed at reducing complications and improving patient outcomes.

List of Leading Companies:

• Boston Scientific Corporation
• Cook Medical
• Teleflex Incorporated
• Medtronic
• Coloplast A/S
• C.R. Bard (Becton Dickinson and Company)
• Alcon
• Stryker Corporation
• Smith & Nephew
• Johnson & Johnson (Ethicon)
• AngioDynamics
• ConvaTec Group PLC
• Medi-Globe
• Gambro (Fresenius Medical Care)
• Urocare Products, Inc.

Report Scope: